Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy

Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy - The ALINET Registry

Evaluation of adherence, persistence and efficacy of treatment with alirocumab 300 mg in a real-life Italian population.

Inclusion Criteria:

- Patients under alirocumab 300mg treatment.

Exclusion Criteria:

• Age < 18 years o > 80 years;
• Patients who refuse to participate and to sign informed consent.